Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20471151 | 0.77 | — | — | |
| SCHEMBL7715753 | 0.72 | ALDH1A1 (0.37) | HSD17B10ALDH1A1 | |
| SCHEMBL2006409 | 0.69 | — | — | |
| SCHEMBL11560173 | 0.69 | HSD17B10 (0.33) | HSD17B10ALDH1A1 | |
| SCHEMBL24799370 | 0.68 | SIGMAR1 (0.31) | — | |
| SCHEMBL5730156 | 0.67 | — | — | |
| SCHEMBL12219336 | 0.67 | — | — | |
| SCHEMBL2006509 | 0.67 | HSD17B10 (0.31) | HSD17B10ALDH1A1 | |
| SCHEMBL8158032 | 0.65 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL29019100 | 0.65 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| CN-114746411-B | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4065575-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2024-01-31 | — | — | EP | disclosed |
| US-20230119316-A1 | Substituted Tricyclic Compounds | LUPIN LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2023-01-19 | — | — | US | disclosed |
| EP-4081521-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| EP-4065575-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105960-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-06-03 | — | — | WO | disclosed |
| US-20210052556-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LTD (IN) | 2021-02-25 | — | — | US | disclosed |
| EP-2670744-B1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LTD (IN) | 2015-05-27 | — | — | EP | disclosed |
| US-20150133424-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-8946432-B2 | Biaryl derivatives as nAChR modulators | LUPIN LIMITED (IN) | 2015-02-03 | — | — | US | disclosed |
| US-20150010505-A1 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150010504-A1 | Antiviral Compounds with a Heterotricycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20140155433-A1 | BIARYL DERIVATIVES AS NACHR MODULATORS | LUPIN LIMITED (IN) | 2014-06-05 | — | — | US | disclosed |
| US-20140018327-A1 | Pyrrole Derivatives as Nicotinic Acetylcholine Receptor Modulators for Use in the Treatment of Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease | LUPIN LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2013-12-12 | — | — | US | disclosed |
| US-20130310419-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LIMITED (IN) | 2013-11-21 | — | — | US | disclosed |
| WO-2013005157-A1 | SULFONE DERIVATIVES AND THEIR USE AS PKM2 MODULATORS FOR THE TREATMENT OF CANCER | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018327-A1 | Pyrrole Derivatives as Nicotinic Acetylcholine Receptor Modulators for Use in the Treatment of Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease | CHRM1, CHRM5, CHRM2 | HSD17B10 3252/4885ALDH1A1 3383/4885 |
| US-20150010505-A1 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety | DDX6, HAVCR2, DHX36 | HSD17B10 2190/4885ALDH1A1 1365/4885 |
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | SOS1, RSU1, KSR1 | HSD17B10 4411/4885ALDH1A1 3879/4885 |
| US-20210052556-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | HSD17B10 1918/4885ALDH1A1 1217/4885 |
| US-20150133424-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | HSD17B10 1874/4885ALDH1A1 1705/4885 |
| US-20130310419-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | CHRNA7, CHRNE, CHRNA5 | HSD17B10 2711/4885ALDH1A1 2246/4885 |
| US-20140155433-A1 | BIARYL DERIVATIVES AS NACHR MODULATORS | CHRM2, CHRM1, CHRM5 | HSD17B10 2751/4885ALDH1A1 2632/4885 |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | CHRNA7, CHRM1, CHRM2 | HSD17B10 2718/4885ALDH1A1 3231/4885 |
| US-20230119316-A1 | Substituted Tricyclic Compounds | SOS1, RSU1, KSR1 | HSD17B10 3860/4885ALDH1A1 3322/4885 |
| US-20150010504-A1 | Antiviral Compounds with a Heterotricycle Moiety | HCCS, UQCRB, HAVCR2 | HSD17B10 2058/4885ALDH1A1 2083/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | HSD17B10 4411/4885ALDH1A1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.